Su­per­nus bags ear­ly-stage CNS drug for $15M up­front in re­newed epilep­sy R&D ef­forts

A few years in­to mar­ket­ing their two epilep­sy drugs, the neu­rol­o­gy and psy­chi­a­try ex­perts at Su­per­nus Phar­ma are go­ing back to the draw­ing board with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.